Hypersensitivity reaction to cisplatin during chemoradiation therapy for gynecologic malignancy.
Hypersensitivity reactions to intravenous cisplatin are rare. The appearance of hypersensitivity reactions in 4 of 25 consecutive patients treated with concomitant pelvic radiation and weekly intravenous cisplatin for gynecologic malignancies is reported. The reactions appeared within hours of cisplatin delivery and included primarily fever, rash, and pruritus. Infection was ruled out by blood cultures and other laboratory studies. Affected patients were treated prophylactically with an antihistamine before subsequent courses of cisplatin, with excellent results. The high rate of hypersensitivity reactions in our series may be attributable to tumor necrosis and cytokine release caused by the pelvic irradiation. Clinicians should be aware of this potential side effect so that early premedication regimens can be instituted to prevent unnecessary toxicity.
Koren
Claude
C
Institute of Oncology, Rabin Medical Center, Beilinson Campus, Petah Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Yerushalmi
Rinat
R
Katz
Alan
A
Malik
Hana
H
Sulkes
Aaron
A
Fenig
Eyal
E
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002945:Cisplatin / Q000009:adverse effects*; D004342:Drug Hypersensitivity / Q000209:etiology*; D016889:Endometrial Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D008875:Middle Aged; D011838:Radiation-Sensitizing Agents / Q000009:adverse effects*; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000532:radiotherapy
D000970:Antineoplastic Agents; D011838:Radiation-Sensitizing Agents; D002945:Cisplatin